提供支持According to 36Kr.com, Yixi Biotech has announced the completion of tens of million yuan in angel round of financing, led by undisclosed investors. Proceeds from the financing will be used for the research and development of alternative treatment protocols, synthetic biological strains, and drugs for the treatment of intestinal microbial diseases.
Founded in Nanjing in 2019, Yixi Biotech provides solutions for the intestinal microbiology sector. It mainly distributes three research and development pipelines for diabetes, depression and tumor reconstitution after tumor chemotherapy.
Yixi Biotech is committed to managing intestinal microorganisms better through the procedure of "detection - intervention - management" so that people can have a healthy intestinal microbial community to avoid many metabolic diseases. At present, Yixi Biotech has established an evidence-based research and development way from collecting data, then cultivating the strains, to developing drugs. The company has cooperated with many hospitals for research and development.
In addition to the research and development of the treatment for gut microbes and metabolic diseases, Yixi Biotech also explores in the field of personalized health management for obesity, hyperglycemia and health assessment. Meanwhile, it provides personalized health management solutions with a so-called health butler based on its R&D achievements.
"The reconstruction of tumor bacteria after chemotherapy will be our key project and we’ll promote it with the oncology department and nutrition department of hospitals. The products will combine with intelligent monitoring equipment to build a real-time data detecting platform, and provide one-to-one health management for patients with chronic diseases together with the health butler," said Dr. Liu Zhenyun, the CEO of Yixi Biotech.
渝公网安备 50011202502165号
